Project Grant R21AI193494
Award Date 8/25/25
Completion Date 7/31/27
Dollars Obligated $153K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
- This federal Project Grant award of $155,000.00 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) on August 25, 2025. The grant supports research to investigate the role of the mitochondrial serine/threonine phosphatase PGAM5 in mitigating gastrointestinal acute radiation syndrome (GI-ARS). The project aims to examine PGAM5's involvement in intestinal stem...
- The U.S. Department of Health and Human Services' National Institutes of Health (NIH) awarded a $149,008 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to evaluate PEG-BPEI as a potential mitigator against gastrointestinal acute radiation syndrome (GI-ARS). The project aims to develop a murine model of partial body irradiation that simulates GI injury while sparing a portion of the...
- This federal Project Grant award of $160,125.00 from the Department of Health and Human Services' National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research to develop engineered microbes as medical countermeasures against gastrointestinal radiation damage. The primary objective is to assess the efficacy of a genetically modified Limosilactobacillus reuteri 6475 probiotic strain in accelerating the recovery of intestinal stem cells and the intestinal...
- The National Institutes of Health (NIH) awarded a $595,009 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to The Trustees of Columbia University to develop MIIST305 as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS) and identify biomarkers of radiation injury and drug efficacy. The project aims to advance the mitigation and treatment of GI-ARS, which can result from a mass casualty radiation event. The minipig model of ARS will be...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel medical countermeasure to treat the deadly gastrointestinal acute radiation syndrome (GI-ARS). The $167,500 award to The Feinstein Institutes for Medical Research, a non-profit medical research organization, will fund a 2-year project to investigate MSP68 as a mitigator of GI-ARS and its ability to promote the...
- This Project Grant award of $157,000 was provided by the U.S. Department of Health and Human Services' National Institutes of Health (NIH) through the Trans-NIH Research Support program (CFDA 93.310). The funding supports the development of UTS-1401, a novel small molecule agent, as a medical countermeasure to mitigate hematopoietic acute radiation syndrome (H-ARS) following a radiation mass casualty event. The research, conducted by the collaborative partnership of Henry Ford Health and...
- This $157,400 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports the development of an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The project aims to establish the efficacy of certain biocompatible amphiphilic block copolymers, developed by Maroon Biotech Corp, in increasing 10-day and 30-day survival rates as well as preserving gut barrier function in a...
- This $158,500 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research to evaluate the efficacy of the natural compound apigenin as a therapeutic countermeasure against gastrointestinal acute radiation syndrome (GI-ARS) in mice. The research team at Stony Brook University will use a specialized partial-body irradiation technique to study the potential of apigenin, given after radiation exposure, to mitigate intestinal damage...
- The federal Project Grant award of $164,500.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310), awarded on August 19, 2025, supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasures. The goal is to create an extracorporeal model based on healthy human GI tissue to enable high-throughput screening of radiomitigators while accounting...
- This is a Cooperative Agreement awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Old Dominion University (ODU) and its research foundation, Odurf, to develop a radiation mitigator called YK-4-250 for treating gastrointestinal acute radiation syndrome (GI-ARS). The $552,787 award aims to investigate the mechanisms by which YK-4-250, a novel Tempol-ARB conjugate, can mitigate GI-ARS and potentially expanded applications as a broader...